Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

6.100 +0.060 (+0.99%)
Streaming Delayed Price Updated: 11:33 AM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 285,911
Open 6.030
Bid (Size) 6.100 (9)
Ask (Size) 6.110 (32)
Prev. Close 6.040
Today's Range 6.010 - 6.120
52wk Range 3.060 - 6.750
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
Via Benzinga
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
From ADMA Biologics, Inc.
Via GlobeNewswire

Performance

YTD
+34.07%
+34.07%
1 Month
+2.69%
+2.69%
3 Month
+23.73%
+23.73%
6 Month
+83.73%
+83.73%
1 Year
+82.63%
+82.63%

More News

Read More
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
Forecasting The Future: 4 Analyst Projections For ADMA Biologics
Via Benzinga
Recap: ADMA Biologics Q4 Earnings
Via Benzinga
Earnings Preview For ADMA Biologics
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For ADMA Biologics
Via Benzinga
Earnings Preview: ADMA Biologics
Via Benzinga
Preview: ADMA Biologics's Earnings
Via Benzinga
ADMA Biologics Announces CFO Transition
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
From ADMA Biologics, Inc.
Via GlobeNewswire
Why Adma Biologics Stock Crushed the Market on Friday
Via The Motley Fool
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
From ADMA Biologics, Inc.
Via GlobeNewswire
Why Adma Biologics Was Trouncing the Market Today
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
From ADMA Biologics, Inc.
Via GlobeNewswire
Why Shares of ADMA Biologics Are Climbing Thursday
Via The Motley Fool
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
From ADMA Biologics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.